| Criterion Text | Inclusion/Exclusion | Disease | Biomarker | Prior Therapy | Criterion Rule |
| --- | --- | --- | --- | --- | --- |
| A history of previously treated brain metastases is allowed, provided that at least 7 days have lapsed between radiation and initiation of pembrolizumab | Inclusion | Brain Metastases | None | Radiation or surgical resection | history of previously treated brain metastases ∧ (7 days have lapsed between radiation and initiation of pembrolizumab) |
| Any brain metastasis >= 20 mm or causing symptoms must be treated with local therapy (i.e. radiation or surgical resection, as clinically appropriate) prior to study enrollment | Inclusion | Brain Metastases | None | Radiation or surgical resection | (brain metastasis >= 20 mm) ∨ (causing symptoms) ∧ local therapy (radiation or surgical resection) |
| Any lesion present at the time of whole brain radiotherapy (WBRT) or included in the stereotactic radiotherapy field (or within 2 mm of the treated lesion) will NOT be considered evaluable unless it is new or documented to have progressed since treatment | Exclusion | Brain Metastases | None | Whole brain radiotherapy (WBRT) or stereotactic radiotherapy | ¬ (lesion present at the time of WBRT or included in the stereotactic radiother